Nutriband Inc. (NASDAQ: NTRB), a developer of transdermal pharmaceutical products, has taken a key step in protecting the commercial identity of its lead product, an abuse-deterrent fentanyl patch. On September 2, the U.S. Patent and Trademark Office (USPTO) issued a Notice of Publication for trademark applications associated with the product. This publication opens a 30-day opposition period; if no objections are filed, the USPTO is expected to issue a Notice of Allowance, moving the trademarks toward final registration.
The fentanyl patch incorporates Nutriband’s proprietary AVERSA™ abuse-deterrent technology, designed to deter abuse, misuse, and accidental exposure to fentanyl, a potent opioid. This is a critical public health concern, as fentanyl misuse has contributed to the opioid crisis. The company highlights that AVERSA™ technology can be integrated into any transdermal patch to prevent diversion and accidental exposure for drugs with abuse potential.
Nutriband estimates that the product has potential peak annual U.S. sales of $80 million to $200 million. The AVERSA™ technology itself is protected by patents in 46 countries, which could provide a competitive moat. The market for abuse-deterrent opioids has been growing amid regulatory and societal pressure to reduce opioid misuse, and this patch addresses both safety and commercial viability.
The USPTO’s Notice of Publication is a procedural milestone that signals the trademarks’ readiness for potential registration. It allows third parties to oppose the mark if they believe it conflicts with existing rights. After this period, the USPTO will issue a Notice of Allowance, after which Nutriband must file a Statement of Use to complete registration. This process helps secure brand recognition and legal protection as the company prepares for commercialization.
For more information on the full press release, visit https://ibn.fm/p1wVE. Additional updates on Nutriband are available at https://ibn.fm/NTRB.
The advancement of trademark protection is important for Nutriband’s business strategy. It not only safeguards the product’s branding but also reinforces the company’s intellectual property portfolio. With patents already secured globally, the trademark protection adds another layer of defense against competitors. This is particularly significant in the pharmaceutical industry, where brand recognition and legal exclusivity are vital for market success.
Moreover, the potential sales figures indicate a substantial market opportunity. If successful, the product could significantly impact Nutriband’s financial performance and shareholder value. For investors, this development signals progress in the company’s regulatory and commercialization pipeline.
Overall, the Notice of Publication is a positive indicator for Nutriband. It brings the company closer to launching a product that could address a critical need in opioid safety while generating substantial revenue. As the opposition period passes and the company moves toward final trademark registration, stakeholders will be watching for further milestones.
